Corcept Therapeutics and Xceleron sign agreement for microdosing study using accelerator mass spectrometry
Corcept Therapeutics and Xceleron announced an agreement for a human microdosing study of one of Corcept's new chemical entities, a selective GR-II antagonist, utilizing Xceleron's Accelerator mass spectrometry (AMS) technology.
In early 2003, Corcept initiated a discovery research program to identify and patent selective GR-II antagonists to develop a pipeline of products for proprietary use. Three distinct series of GR-II antagonists were identified. These compounds appear to be as potent as Corcept's lead product CORLUX(r) in blocking cortisol but, unlike CORLUX, they do not block the progesterone or other steroid receptors. Corcept will evaluate one of the compounds, one which develops particularly high plasma and brain concentrations in an animal model, in a human microdosing study using Xceleron's AMS technology.
Xceleron will carry out the work using ultra-sensitive AMS. This most sensitive measuring device enables human drug-metabolite profiling to be performed in the early stages of clinical development. This type of analysis allows drug developers to detect and measure ultra-low levels of both known and previously unknown metabolites producing data that isn't available using other analytical techniques. Early human profiling also helps identify the most suitable species for use in long term toxicology and pharmacology studies.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Last viewed contents
Metrohm celebrates 25 years of ion chromatography
Fluorotechnics appoints James Walker CEO - Duncan Veal appointed to key role of chief technology officer
Varian, Inc. Completes Electronics Manufacturing Divestiture - Varian, Inc. to Focus Efforts on Scientific Instruments and Vacuum Technologies Businesses
Hazardous ingredients in batteries - Trust, but verify! A long and winding road to an innovative method
JG Finneran Associates Appoints Chebios as its Exclusive Distributor in Italy
Ring of complex organic molecules around newborn star discovered
Researchers discover new genetic mutation that causes male infertility
Exonhit presents new opportunities in blood diagnostics in neurodegenerative diseases - Identification of new markers for BSE in collaboration with Roche Applied Science
Wanted: The faces of the chemical crowd